Core Points - The document outlines the independent director system of Shanghai Sailun Biotechnology Co., Ltd, aiming to enhance corporate governance and protect the rights of all shareholders, especially minority shareholders [1][2][3] - Independent directors must not have any direct or indirect interests that could affect their independent judgment and are required to fulfill their duties with integrity and diligence [2][3][4] Group 1: Independent Director Qualifications - Independent directors should not hold any other positions within the company and must not have any relationships that could compromise their independence [2][3] - The company will have three independent directors, including at least one accounting professional with relevant qualifications [4][5] - Candidates for independent directors must meet specific criteria, including legal qualifications, independence, and relevant work experience [8][9] Group 2: Responsibilities and Powers - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice to enhance decision-making [19][20] - They have special powers, including the ability to hire external consultants, call for shareholder meetings, and express independent opinions on matters that may harm the company or minority shareholders [20][21] - Independent directors must attend board meetings and can delegate their voting rights if unable to attend [19][20] Group 3: Appointment and Termination - Independent directors are nominated by the board or shareholders and must be approved by the shareholders' meeting [11][12] - Their term aligns with that of other directors, with a maximum consecutive term of six years [17][18] - The company must promptly disclose reasons for any termination of independent directors [17][18] Group 4: Reporting and Compliance - Independent directors must report any issues that hinder their ability to perform their duties to the relevant authorities [26][27] - They are required to conduct annual self-assessments of their independence and submit reports to the board [29][30] - The company must provide necessary resources and support to independent directors to ensure they can fulfill their responsibilities effectively [34][35]

第四条 关联交易活动应遵循公平、公正、公开的原则和诚实信用原则， 不得损害公司和非关联股东的合法权益，关联交易的价格原则上不能偏离市场 独立第三方的价格或收费的标准。 第五条 关联交易是指公司或者控股子公司与公司关联人发生的转移资源 或义务的事项，包括但不限于下列事项： （十七）根据实质重于形式原则认定的其他通过约定可能引致资源或者义 务转移的事项，包括向与关联人共同投资的公司提供大于其股权比例或投资比 例的财务资助、担保以及放弃向与关联人共同投资的公司同比例增资或优先受 让权等； 第一章 总 则 第一条 为保证上海赛伦生物技术股份有限公司（以下简称"公司"）与 关联方之间的关联交易符合公平、公正、公开的原则，确保公司的关联交易行 为不损害公司和非关联股东的合法权益，根据《中华人民共和国公司法》、《 中华人民共和国证券法》、《上海证券交易所科创板股票上市规则》（以下简 称"《上市规则》"）等有关法律、法规、规范性文件及《上海赛伦生物技术 股份有限公司章程》（以下简称"《公司章程》"）等的规定，结合公司实际 情况，制订本制度。 第二条 公司与关联人之间的关联交易除遵守有关法律、法规、规范性文 件及《公司章程》的 ...

General Principles - The compensation management system for directors and senior management of Shanghai Sailun Biotechnology Co., Ltd. aims to enhance work motivation and creativity, thereby improving operational efficiency and management standards [2] - The system is based on relevant laws and regulations, including the Company Law of the People's Republic of China and the Articles of Association of the company [2] Applicability - The compensation management system applies to the company's directors and senior management, which includes the general manager, deputy general managers, board secretary, financial director, and other personnel recognized by the board [2] Compensation Principles - Compensation for directors and senior management is determined based on company size and performance, ensuring alignment with market value [2] - The principles include reflecting income levels in accordance with company scale and performance, aligning compensation with job value and responsibilities, supporting long-term company interests, and balancing incentives and constraints [2] Compensation Management Structure - The board of directors is responsible for reviewing the compensation of senior management, while the shareholders' meeting reviews the compensation of directors [3] - The Compensation and Assessment Committee of the board manages the compensation plans and conducts annual performance evaluations [3] Compensation Standards - Compensation for board members includes allowances for independent directors, which are subject to approval by the board and shareholders [3][4] - Senior management compensation consists of basic salary and performance-based pay, with the basic salary determined by position, responsibility, capability, and market salary trends [4] Performance-Based Compensation - Performance-based compensation is linked to the company's performance evaluation system and is determined based on assessment results [4] Payment Schedule - Director allowances and basic salaries are paid monthly, while performance bonuses are distributed based on the assessment cycle, which runs from January 1 to December 31 each year [5] Conditions for Compensation Reduction - The board may decide to reduce or withhold performance compensation or allowances if there are significant losses due to poor decision-making or serious violations of company regulations [5] Compensation Adjustment Criteria - The Compensation and Assessment Committee adjusts compensation based on industry salary increases, inflation, company profitability, organizational changes, and specific job responsibilities [6][7] Implementation - The compensation management system will be implemented upon approval by the shareholders' meeting and is subject to modification by the board [7]

第一章 总则 第一条 为贯彻证券市场公开、公平、公正原则，进一步规范上海赛伦生物 技术股份有限公司（以下简称"公司"）控股股东、实际控制人的行为，切实保 护公司和其他股东的合法权益，根据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》等相 关法律、法规、规范性文件及《上海赛伦生物技术股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，并结合公司实际情况，特制定本规范。 第二条 本规范适用于本公司的控股股东、实际控制人。 以下主体的行为视同控股股东、实际控制人行为，比照适用本规范相关规定： （一）控股股东、实际控制人直接或间接控制的法人、其他组织（本公司及 其控股子公司除外）、一致行动人； （二）控股股东、实际控制人为自然人的，其父母、配偶和子女； （三）第一大股东； （四）上海证券交易所认定的其他主体。 第三条 本规范所称控股股东是指持有公司股份占公司股本总额超过50%的 股东，或者持有股份的比例虽然未超过50%，但依其持有的股份所享有的表决权已 足以对股东会的决议产生重大影响的股东。 本规范所称实际控制人是指通过投资关系、协议或者其他安排，能 ...

Core Points - The article outlines the measures taken by Shanghai Sailun Biotechnology Co., Ltd. to prevent the controlling shareholder, actual controller, and related parties from occupying company funds [2][3][4] - The company aims to establish a long-term mechanism to safeguard the interests of all shareholders and stakeholders [2][3] Group 1: General Principles - The system applies to fund management between the controlling shareholder, actual controller, and related parties with the company and its subsidiaries [3] - The definition of controlling shareholders, actual controllers, and related transactions follows the regulations of the Shanghai Stock Exchange [3] Group 2: Types of Fund Occupation - Fund occupation includes both operational and non-operational fund occupation [4] - Operational fund occupation refers to fund occupation arising from related transactions in production and operation [4] - Non-operational fund occupation includes various forms such as payment of wages, debts, and other expenses on behalf of the controlling shareholder or related parties [4][5] Group 3: Prevention Measures - The company prohibits any form of fund occupation by the controlling shareholder or related parties [5][6] - Strict procedures and disclosure obligations must be followed for any operational fund transactions with the controlling shareholder or related parties [6][7] - The board of directors is responsible for establishing a verification system to monitor transactions and fund flows with the controlling shareholder and related parties [7][8] Group 4: Responsibilities and Accountability - The board of directors and senior management must diligently fulfill their responsibilities to protect company funds [9][10] - Any violation of the fund occupation rules by the controlling shareholder or related parties will result in liability for damages [10][12] - The company must take protective measures to minimize losses caused by fund occupation or transfer by the controlling shareholder or related parties [10][11]

Core Points - The document outlines the rules for the operation of the shareholders' meeting of Shanghai Sailun Biotechnology Co., Ltd, ensuring compliance with relevant laws and regulations [2][3][4] - The company must hold annual and temporary shareholders' meetings, with specific timelines for notification and execution [4][5][6] - Legal opinions must be obtained for the meeting's procedures, attendance qualifications, and voting results [3][4][5] Group 1 - The company is required to report to the China Securities Regulatory Commission and the Shanghai Stock Exchange if it cannot hold a shareholders' meeting within the specified timeframe [3][4] - The board of directors must convene the shareholders' meeting within the legal timeframe and respond to requests from independent directors and shareholders holding more than 10% of shares [4][5][6] - The audit committee can convene a temporary shareholders' meeting if the board fails to do so within the stipulated time [4][5] Group 2 - Shareholders holding more than 1% of shares can propose additional agenda items for the meeting, provided they comply with legal and regulatory requirements [6][7] - Notifications for the annual and temporary shareholders' meetings must include detailed information about the meeting and the agenda items [6][7][8] - The company must ensure that all shareholders can attend the meeting, either in person or through authorized representatives [8][9] Group 3 - Voting procedures must be clearly defined, and the results must be disclosed promptly after the meeting [12][15] - The company must maintain confidentiality regarding the voting process and ensure that all relevant documentation is preserved for ten years [15][16] - The board of directors is responsible for executing the resolutions passed during the shareholders' meeting in a timely manner [17][18]

第一章 总 则 第一条 为保证上海赛伦生物技术股份有限公司（以下简称"公司"）与 关联方之间的关联交易符合公平、公正、公开的原则，确保公司的关联交易行 为不损害公司和非关联股东的合法权益，根据《中华人民共和国公司法》、《 中华人民共和国证券法》、《上海证券交易所科创板股票上市规则》（以下简 称"《上市规则》"）等有关法律、法规、规范性文件及《上海赛伦生物技术 股份有限公司章程》（以下简称"《公司章程》"）等的规定，结合公司实际 情况，制订本制度。 第二条 公司与关联人之间的关联交易除遵守有关法律、法规、规范性文 件及《公司章程》的规定外，还需遵守本制度的有关规定。 第三条 公司与关联人之间的关联交易应签订书面协议。协议的签订应当 遵循平等、自愿、等价、有偿的原则，协议内容应明确、具体。 第四条 关联交易活动应遵循公平、公正、公开的原则和诚实信用原则， 不得损害公司和非关联股东的合法权益，关联交易的价格原则上不能偏离市场 独立第三方的价格或收费的标准。 第五条 关联交易是指公司或者控股子公司与公司关联人发生的转移资源 或义务的事项，包括但不限于下列事项： 1 （一）购买或者出售资产； （二）对外投资（购买银行理 ...

第四条 公司董事会设审计委员会，依据相关法律、法规以及公司《审计委 员会议事规则》的规定指导和监督公司内部审计制度的建立和实施。审计委员会 负责监督及评估内部审计工作。 审计委员会下设审计部作为公司的内部审计机构，对公司业务活动、风险管 理、内部控制、财务信息等事项进行监督检查。 第一章 总则 第一条 为了进一步规范上海赛伦生物技术股份有限公司（以下简称"公司"） 内部审计工作，提高审计工作质量，实现公司内部审计工作规范化、标准化，发 挥内部审计工作在促进企业经济管理、提高经济效益中的作用,根据《中华人民 共和国审计法》、《审计署关于内部审计工作的规定》、《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》、《上海赛伦生物技术股份有限公司 章程》（以下简称"《公司章程》"）及相关法律法规的规定，并结合公司实际情况， 制定公司内部审计制度（以下简称"本制度"）。 第二条 本制度适用于公司各部门、纳入公司合并会计报表的子公司、具有 重大影响的参股公司以及分公司（如有）的内部审计管理。 第三条 本制度所称内部审计，是指由公司内部机构或人员，对公司内部控 制和风险管理的有效性、财务信息的真实性和完整性 ...

第一章 总 则 第一条 为了规范上海赛伦生物技术股份有限公司（以下简称"公司"） 募集资金管理，提高募集资金使用效率，切实保护广大投资者的利益，依据《 中华人民共和国公司法》、《中华人民共和国证券法》（以下简称"《证券法》 "）、《上市公司募集资金监管规则》、《上海证券交易所科创板股票上市规 则》等法律、法规以及《上海赛伦生物技术股份有限公司章程》（以下简称" 《公司章程》"），结合公司实际情况，制定本制度。 第二条 本制度所称"募集资金"，系指公司通过发行股票或者其他具 有股权性质的证券（包括首次公开发行股票、配股、增发、发行可转换公司 债券、发行分离交易的可转换公司债券等）向投资者募集并用于特定用途的 资金，但不包括公司实施股权激励计划募集的资金。 第二章 募集资金存储 公司募集资金应当存放于经董事会批准设立的专用账户（以下 简称"募集资金专户"）集中管理和使用。募集资金专户的设立和募集资金 的存储由公司财务部办理。 募集资金专户不得存放非募集资金或用作其它用途。 第七条 募集资金到位后，公司应及时办理验资手续。募集的货币资金须 经具有《证券法》规定的资格的会计师事务所审验并出具验资报告。实物资产 须经相 ...

上海赛伦生物技术股份有限公司章程 上海赛伦生物技术 股份有限公司 章程 二零二五年七月 1 | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第一节 | 股份发行 4 | | 第二节 | 股份增减和回购 5 | | 第三节 | 股份转让 6 | | 第四章 | 股东和股东会 7 | | 第一节 | 股东的一般规定 7 | | 第二节 | 控股股东和实际控制人 10 | | 第三节 | 股东会的一般规定 11 | | 第四节 | 股东会的召集 14 | | 第五节 | 股东会的提案与通知 16 | | 第六节 | 股东会的召开 17 | | 第七节 | 股东会的表决和决议 19 | | 第五章 | 董事会 23 | | 第一节 | 董事 23 | | 第二节 | 董事会 26 | | 第三节 | 独立董事 29 | | 第四节 | 董事会专门委员会 31 | | 第六章 | 高级管理人员 33 | | 第七章 | 财务会计制度、利润分配和审计 34 | | 第一节 | 财务会计制度 34 | | --- | --- | | 第二节 ...